Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with Covid-19 Pneumonia

Bibliographic Data

ID15465123
AuthorsRiccardo Scotto (0000-0002-0178-2986, University of Naples Federico II), Biagio Pinchera (0000-0002-8685-5434, University of Naples Federico II, corresponding author), Francesco Perna (0000-0002-2177-1184, Ospedale Monaldi), Lidia Atripaldi (0000-0003-4370-7682, Ospedale Monaldi), G Agnese (0000-0003-4002-0930, University of Naples Federico II), Agnese Giaccone (University of Naples Federico II), Davide Sequino (0000-0002-8718-5989, Ospedale Monaldi), Emanuela Zappulo (0000-0002-7660-7939, University of Naples Federico II), Alessia Sardanelli (University of Naples Federico II), Nicola Schiano Moriello (0000-0001-8474-4776, University of Naples Federico II), Anna Agnese Stanziola (Ospedale Monaldi), Anna Stanziola (University of Naples Federico II), Marialuisa Bocchino (0000-0001-5477-072X, Ospedale Monaldi), Ivan Gentile (0000-0002-5199-8451, University of Naples Federico II), Alessandro Sanduzzi (0000-0002-0977-2643, Ospedale Monaldi)
Year2021
Volume18
Issue4
Pages2078-2078
Publication date2021-02-20
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph18042078
PMID33672761
OpenAlexW3131824631
LanguageEN
References cited33

KL-6 is a sialoglycoprotein antigen which proved elevated in the serum of patients with different interstitial lung diseases, especially in those with a poorer outcome. Given that interstitial pneumonia is the most common presentation of SARS-CoV2 infection, we evaluated the prognostic role of KL-6 in patients with COVID-19 pneumonia. Patients with COVID-19 pneumonia were prospectively enrolled. Blood samples were collected at the time of enrolment (TOE) and on day 7 (T1). Serum KL-6 concentrations were measured by chemiluminescence enzyme immunoassay using a KL-6 antibody kit (LUMIPULSE G1200, Fujirebio) and the cut-off value was set at >1000 U/mL. Fifteen out of 34 enrolled patients (44.1%) died. Patients with unfavourable outcome showed significantly lower P/F ratio and higher IL-6 values and plasmatic concentrations of KL-6 at TOE compared with those who survived (median KL-6: 1188 U/mL vs. 260 U/mL, p 1000 U/mL resulted independently associated with death (aOR: 11.29, p 1000 U/mL resulted independently associated with death and showed good accuracy in predicting a poorer outcome. KL-6 may thus represent a quick, inexpensive, and sensitive parameter to stratify the risk of severe respiratory failure and death

Atypical pneumonia · Coronavirus disease 2019 (COVID-19 · Disease · Pneumonia · Dermatological and COVID-19 studies · Inhalation and Respiratory Drug Delivery · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Medicine · Gastroenterology · Immunology · Internal Medicine

Tools

Open DOIOpen Access